Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 4 (February 1), 2008: pp. 633-638
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2008.14.0095

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meyers, P. A.
Right arrow Articles by Grier, H. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyers, P. A.
Right arrow Articles by Grier, H. E.
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Delicious   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Correspondence

  • Osteosarcoma: The Same Old Drugs or More?
    Stefan S. Bielack, Neyssa Marina, Stefano Ferrari, Lee J. Helman, Sigbjørn Smeland, Jeremy S. Whelan, and Gregory H. Reaman
    JCO 2008 26: 3102-3103 [Full Text]
  • Complexities in Interpretation of Osteosarcoma Clinical Trial Results
    Sally Hunsberger, Boris Freidlin, and Malcolm A. Smith
    JCO 2008 26: 3103-3104 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
J. P. Lagmay, M. D. Krailo, H. Dang, A. Kim, D. S. Hawkins, O. Beaty III, B. C. Widemann, T. Zwerdling, L. Bomgaars, A.-M. Langevin, et al.
Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward
J. Clin. Oncol., September 1, 2016; 34(25): 3031 - 3038.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. J. Mason, J. S. Gnanandarajah, J. B. Engiles, F. Gray, D. Laughlin, A. Gaurnier-Hausser, A. Wallecha, M. Huebner, and Y. Paterson
Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma
Clin. Cancer Res., September 1, 2016; 22(17): 4380 - 4390.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
M. G. Netea, L. A. B. Joosten, E. Latz, K. H. G. Mills, G. Natoli, H. G. Stunnenberg, L. A. J. ONeill, and R. J. Xavier
Trained immunity: A program of innate immune memory in health and disease
Science, April 22, 2016; 352(6284): aaf1098 - aaf1098.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. S. Isakoff, S. S. Bielack, P. Meltzer, and R. Gorlick
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
J. Clin. Oncol., September 20, 2015; 33(27): 3029 - 3035.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. R. Weiss
To B(MP-2) or Not To B(MP-2): Cytokines and Tumor Surgery--Response
Clin. Cancer Res., September 1, 2015; 21(17): 4023 - 4023.
[Full Text] [PDF]


Home page
JCOHome page
S. S. Bielack, S. Smeland, J. S. Whelan, N. Marina, G. Jovic, J. M. Hook, M. D. Krailo, M. Gebhardt, Z. Papai, J. Meyer, et al.
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
J. Clin. Oncol., July 10, 2015; 33(20): 2279 - 2287.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
C. A. Bellera, N. Penel, M. Ouali, S. Bonvalot, P. G. Casali, O. S. Nielsen, M. Delannes, S. Litiere, F. Bonnetain, T. S. Dabakuyo, et al.
Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
Ann. Onc., May 1, 2015; 26(5): 865 - 872.
[Abstract] [Full Text] [PDF]


Home page
Sci Transl MedHome page
H. Bruns, M. Buttner, M. Fabri, D. Mougiakakos, J. T. Bittenbring, M. H. Hoffmann, F. Beier, S. Pasemann, R. Jitschin, A. D. Hofmann, et al.
Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma
Science Translational Medicine, April 8, 2015; 7(282): 282ra47 - 282ra47.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
The ESMO/European Sarcoma Network Working Group
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann. Onc., September 1, 2014; 25(suppl_3): iii113 - iii123.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Khanna, T. M. Fan, R. Gorlick, L. J. Helman, E. S. Kleinerman, P. C. Adamson, P. J. Houghton, W. D. Tap, D. R. Welch, P. S. Steeg, et al.
Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma
Clin. Cancer Res., August 15, 2014; 20(16): 4200 - 4209.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
T. JENTZSCH, B. ROBL, M. HUSMANN, B. BODE-LESNIEWSKA, and B. FUCHS
Worse Prognosis of Osteosarcoma Patients Expressing IGF-1 on a Tissue Microarray
Anticancer Res, August 1, 2014; 34(8): 3881 - 3889.
[Abstract] [Full Text] [PDF]


Home page
ILAR JHome page
J. M. Fenger, C. A. London, and W. C. Kisseberth
Canine Osteosarcoma: A Naturally Occurring Disease to Inform Pediatric Oncology
ILAR J, January 1, 2014; 55(1): 69 - 85.
[Abstract] [Full Text] [PDF]


Home page
J Natl Compr Canc NetwHome page
J. S. Biermann, D. R. Adkins, M. Agulnik, R. S. Benjamin, B. Brigman, J. E. Butrynski, D. Cheong, W. Chow, W. T. Curry, D. A. Frassica, et al.
Bone Cancer
J Natl Compr Canc Netw, June 1, 2013; 11(6): 688 - 723.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Pignochino, C. Dell'Aglio, M. Basirico, F. Capozzi, M. Soster, S. Marchio, S. Bruno, L. Gammaitoni, D. Sangiolo, E. Torchiaro, et al.
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
Clin. Cancer Res., April 15, 2013; 19(8): 2117 - 2131.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. A. Janeway and R. G. Maki
New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents
Clin. Cancer Res., November 1, 2012; 18(21): 5837 - 5844.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
The ESMO / European Sarcoma Network Working Group
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann. Onc., October 1, 2012; 23(suppl_7): vii100 - vii109.
[Full Text] [PDF]


Home page
JCOHome page
S. Ferrari, P. Ruggieri, G. Cefalo, A. Tamburini, R. Capanna, F. Fagioli, A. Comandone, R. Bertulli, G. Bisogno, E. Palmerini, et al.
Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1
J. Clin. Oncol., June 10, 2012; 30(17): 2112 - 2118.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. G. Maki
Ifosfamide in the Neoadjuvant Treatment of Osteogenic Sarcoma
J. Clin. Oncol., June 10, 2012; 30(17): 2033 - 2035.
[Full Text] [PDF]


Home page
Ann OncolHome page
J. S. Whelan, R. C. Jinks, A. McTiernan, M. R. Sydes, J. M. Hook, L. Trani, B. Uscinska, V. Bramwell, I. J. Lewis, M. A. Nooij, et al.
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials
Ann. Onc., June 1, 2012; 23(6): 1607 - 1616.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Grignani, E. Palmerini, P. Dileo, S. D. Asaftei, L. D'Ambrosio, Y. Pignochino, M. Mercuri, P. Picci, F. Fagioli, P. G. Casali, et al.
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
Ann. Onc., February 1, 2012; 23(2): 508 - 516.
[Abstract] [Full Text] [PDF]


Home page
J Bone Joint Surg AmHome page
J. H. Healey
Commentary on an article by Kyucheol Noh, MD, et al.: "Targeting Inflammatory Kinase as an Adjuvant Treatment for Osteosarcomas"
jbjsam, April 20, 2011; 93(8): e42 - e42.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. P. Buddingh, M. L. Kuijjer, R. A. J. Duim, H. Burger, K. Agelopoulos, O. Myklebost, M. Serra, F. Mertens, P. C. W. Hogendoorn, A. C. Lankester, et al.
Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents
Clin. Cancer Res., April 15, 2011; 17(8): 2110 - 2119.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
J. Ritter and S. S. Bielack
Osteosarcoma
Ann. Onc., October 1, 2010; 21(suppl_7): vii320 - vii325.
[Abstract] [Full Text] [PDF]


Home page
J Natl Compr Canc NetwHome page
R. Chugh
Experimental Therapies and Clinical Trials in Bone Sarcoma
J Natl Compr Canc Netw, June 1, 2010; 8(6): 715 - 725.
[Abstract] [Full Text] [PDF]


Home page
J Natl Compr Canc NetwHome page
C. D. Morris
Pelvic Bone Sarcomas: Controversies and Treatment Options
J Natl Compr Canc Netw, June 1, 2010; 8(6): 731 - 737.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
P. C. W. Hogendoorn, On behalf of the ESMO/EUROBONET Working Group, Writing committee:, N. Athanasou, S. Bielack, E. De Alava, A. P. D. Tos, S. Ferrari, H. Gelderblom, R. Grimer, et al.
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2010; 21(suppl_5): v204 - v213.
[Full Text] [PDF]


Home page
J Biol ChemHome page
G. Cheng, J. Sun, Z. G. Fridlender, L.-C. S. Wang, L.-M. Ching, and S. M. Albelda
Activation of the Nucleotide Oligomerization Domain Signaling Pathway by the Non-bacterially Derived Xanthone Drug 5'6-Dimethylxanthenone-4-acetic Acid (Vadimezan)
J. Biol. Chem., April 2, 2010; 285(14): 10553 - 10562.
[Abstract] [Full Text] [PDF]


Home page
Cleveland Clinic Journal of MedicineHome page
S. A. LIETMAN and M. J. JOYCE
Bone sarcomas: Overview of management, with a focus on surgical treatment considerations
, March 1, 2010; 77(Suppl_1): S8 - S12.
[Abstract] [Full Text] [PDF]


Home page
J Bone Joint Surg AmHome page
V. O. Lewis
What's New in Musculoskeletal Oncology
jbjsam, June 1, 2009; 91(6): 1546 - 1556.
[Full Text] [PDF]


Home page
Ann OncolHome page
S. Bielack, D. Carrle, P. G. Casali, and On behalf of the ESMO Guidelines Working Group
Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv137 - iv139.
[Full Text] [PDF]


Home page
aacredbookHome page
K. A. Janeway
Modeling of Molecular Aberrations in Pediatric Cancer
Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 119 - 121.
[Full Text] [PDF]


Home page
JCOHome page
S. S. Bielack, N. Marina, S. Ferrari, L. J. Helman, S. Smeland, J. S. Whelan, and G. H. Reaman
Osteosarcoma: The Same Old Drugs or More?
J. Clin. Oncol., June 20, 2008; 26(18): 3102 - 3103.
[Full Text] [PDF]


Home page
JCOHome page
S. Hunsberger, B. Freidlin, and M. A. Smith
Complexities in Interpretation of Osteosarcoma Clinical Trial Results
J. Clin. Oncol., June 20, 2008; 26(18): 3103 - 3104.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meyers, P. A.
Right arrow Articles by Grier, H. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyers, P. A.
Right arrow Articles by Grier, H. E.
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Delicious   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online